EDITORIAL

Faltering Under Pressure: Limitations to Noninvasive Diastolic Function Assessments

James P. MacNamara, MD; Satyam Sarma, MD

Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence, largely driven by an aging and more obese global population.1 Although pharmacologic treatment options for HFpEF have expanded, one of the key unmet challenges is identifying patients who actually have HFpEF. Dyspnea is a common symptom among older and obese adults, and noninvasive cardiac testing often fails to adequately discriminate cardiac causes of dyspnea from noncardiac causes.2 The gold standard for diagnosing patients with HFpEF is invasive measure of cardiac filling pressures, either at rest or during exercise.3 In clinical practice, invasive measure of pressures is rarely done and typically reserved for patients with persistent symptoms of unexplained dyspnea. Rather, the diagnosis is based on the presence of patient symptoms, evidence for diastolic dysfunction by echocardiography, and elevated cardiac biomarkers of ventricular pressure overload. The sensitivity for this approach varies substantially, ranging from 25% to 80%.4–6 In patients who are clinically euvolemic, mildly hypervolemic, or early in their disease state, echocardiography-based pressure and volume criteria for diastolic dysfunction may be normal or indeterminate.7 As an example of this imprecision, the distribution of diastolic dysfunction severity in several randomized clinical trials of patients with HFpEF is highly heterogeneous, with over half of patients enrolled in these trials having either normal or mild diastolic dysfunction,8–10 despite meeting clinical criteria for entry into the studies. With echocardiography being a core modality for diagnosis of diastolic dysfunction, understanding the causes for this heterogeneity among patients is critical.

See Article by van de Bovenkamp et al.

In 2016, the American Society of Echocardiography and the European Association of Cardiovascular Imaging released updated recommendations evaluating left ventricular (LV) diastolic function by echocardiography.11 The revised guidelines attempted to simplify the 2009 diastolic function guidelines. Using simple 4-point diagnostic criteria, the updated algorithm was designed to improve clinical utility and interpretation by referring providers. An increased emphasis was placed on identifying LV filling pressures and, as such, markers of LV relaxation and end diastole (eg, mitral A wave and pulmonary vein atrial systolic reversal) were deemphasized, although not fully eliminated. Of the 4 current diagnostic criteria, 3 (right ventricular systolic pressure >2.8 m/s, left atrial [LA] volume >34 mL/m², and E/e’ >14) reflect elevated pressure and remodeling associated with a chronic volume overloaded state.11 Although these thresholds were derived from patients who had a clear diagnosis of heart failure, it is unknown how well these cut points accurately and consistently identify patients undergoing evaluation for suspected HFpEF.

Key Words: Editorials • diastolic function • heart failure with preserved ejection fraction • hemodynamics
The current study by van de Bovenkamp and co-authors in this issue of the Journal of the American Heart Association (JAHA) attempts to address this important question. In a retrospective evaluation of 204 patients undergoing work up for dyspnea, screened to exclude greater than moderate valvular dysfunction and depressed LV function, the authors compared the diagnostic accuracy of individual components of the updated diastolic function guidelines in identifying elevated pulmonary capillary wedge pressure (PCWP), defined as >15 mm Hg. Approximately 40% of patients had elevated PCWP, most of whom had clinical evidence for volume overload or congestion. The study authors found weak to no correlation between right ventricular systolic pressure, tissue Doppler early relaxation velocities (e’), and PCWP. There were modest correlations between LA volumes and E/e’. Approximately 25% of patients had indeterminate diastolic dysfunction. Sensitivity for the diastolic function algorithm was 35%. In contrast, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels and H2FPEF score had higher sensitivities but lower specificities.

The study has several strengths. In addition to a relatively large sample size, PCWP was measured at end expiration, minimizing respiratory influences on hemodynamics. Echocardiographic parameters were measured blinded to the hemodynamic assessment. There are some important limitations to note. The study, similar to prior studies from other groups, was retrospective in nature. This raises the potential for residual confounding related to nonstandard algorithmic approaches to evaluating dyspnea on exertion. A prospectively-designed study with a standardized approach to evaluating dyspnea with echocardiogram, serum biomarkers, and right-sided heart catheterization may allow for more controlled patient selection and enrollment. Second, the echocardiogram and right-sided heart catheter were not performed simultaneously, with an interquartile range of −6 to 45 days between catheterization and echocardiogram. Given hemodynamic status can fluctuate day to day, a closer temporal alignment of procedures, although not always clinically practical, may have provided stronger correlation between noninvasive and invasive measurements.

With this study, van de Bovenkamp et al. have added important context and additional data to the growing understanding that echocardiography is not currently suited to detect HFpEF. Although the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines do not reference the use of American Society of Echocardiography diastolic guidelines in their algorithms to diagnosis of HFpEF, the graded classification of diastolic dysfunction presented in echocardiographic reports is what most clinicians use to make decisions. Diastolic function is a complex and multifactorial process that combines the LV-LA pressure gradient, passive and active relaxation, ventricular restoring forces, and end-diastolic LV compliance. Of these processes, the LV-LA pressure gradient is the easiest to measure (through mitral inflow velocity). Unfortunately, mitral inflow velocities do not follow a linear decline from “normal” to pathologic. The E/e’ ratio has become a mainstay for the assessment of filling pressures because of its simplicity and ability to predict cardiac events in patients with established cardiac disease. Yet, E/e’ is significantly less sensitive at low or moderate levels (<14) and does not track with filling pressures over time. Finally, both LV relaxation and compliance worsen with sedentary aging, and the point at which “normal” age-related changes transition to diastolic dysfunction, resulting in pathologic increase in PCWP, is unknown. Future studies of diastolic markers and algorithms must consider the influence of age and fitness on the markers themselves and independent risk of developing heart failure. For instance, e’ is highly correlated with age, and many healthy seniors have e’ velocities below current diastolic function thresholds (septal e’ <7 cm/s, lateral e’ <10 cm/s). Given HFpEF is a disease primarily of the aged, the discriminant utility for e’ in differentiating HFpEF from healthy aging is negligible at >5 cm/s. To date, no one marker or simple battery of markers has been successful in capturing the scope and complexity of diastolic dysfunction. In its current state, echocardiographic assessment of diastolic function is generally unable to provide diagnostic clarity in patients with undifferentiated dyspnea.

How can echocardiography become more useful for clinicians in the evaluation for HFpEF? There are 3 important unmet needs for the noninvasive assessment of patients with dyspnea: (1) improved identification of elevated resting LV filling pressures, (2) noninvasive detection of exertional increases in LV filling pressures, and (3) identification of abnormalities in diastolic relaxation. The addition of novel markers of LA function, including LA strain and volumetric changes, may improve the identification of elevated LA pressures. The noninvasive “diastolic stress test” has a growing body of evidence, but further validation using invasive hemodynamic protocols is needed. Diastolic stress testing also requires specialized equipment in the form of a semirecumbent cycle and an experienced sonographer. Finally, dividing diastolic relaxation into its constituent components may elucidate novel markers of structural remodeling and function. Our group has recently demonstrated the interconnectedness between systole and diastole via assessments of systolic-diatolic coupling, which describes the contribution of systolic contraction toward early diastolic recoil. This relationship, driven primarily by ventricular restoring forces,
forces, is independent of LA pressure and significantly reduced in HfPEF. Further validation is needed to
determine if markers, such as systolic diastolic coupling, can detect early stages of HfPEF.

Assessment of diastolic function remains a major clinical challenge. As HfPEF continues to grow in
scope, more sensitive tools to identify, phenotype, and track therapeutic improvement are needed. Detection
of early-stage HfPEF, in which LV and LA structural remodelling have not become fully manifest or are rela-
tively euvolemic, will likely continue to be problematic. A more thorough understanding of the physiological
features of diastole and cardiac motion will be needed to identify and develop novel noninvasive markers. Until
then, a multimodality approach to dyspnea evaluation, incorporating pretest likelihood, serum biomarkers,
exercise testing, and echocardiography, is essential, keeping in mind echocardiography will be a compo-
nent, and not the core determinant, of evaluation.

REFERENCES

1. van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and
ventricular dysfunction in older adults over time: a systematic review. Eur J Heart Fail. 2016;18:242–252. doi: 10.1002/ejhf.483
2. Ramalho SHR, Santos M, Claggett B, Matsushita K, Kitzman DW, Loehr L, Solomon SD, Skali H, Shah AM. Association of undifferentiated dys-
pnea in late life with cardiovascular and noncardiovascular dysfunction: a cross-sectional analysis from the ARIC study. JAMA Netw Open. 2019;2:e193521. doi: 10.1001/jamanetworkopen.2019.5321
3. Pieske B, Tachópe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, et al. How to diagnose heart
failure with preserved ejection fraction: the HFA-PFEF diagnostic algo-
rithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297–3317. doi: 10.1093/eurheartj/ehz641
4. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in out-
patients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol. 2010;55:1701–1710. doi: 10.1016/j.jacc.2009.11.076
5. Lam CS, Roger VL, Rodheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection
fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–
1126. doi: 10.1016/j.jacc.2008.11.051
6. Obokata M, Reddy YNV, Borlaug BA. The role of echocardiography in heart failure with preserved ejection fraction: what do we want from im-
aging? Heart Fail Clin. 2019;15:241–256. doi: 10.1016/j.hfc.2018.12.004
7. Mittra SS, Shah SJ, Thomas JD. A test in context: E/A and E/e’ to as-
sess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol. 2017;69:1451–1464. doi: 10.1016/j.jacc.2016.12.037
8. Shah AM, Claggett B, Switzer NK, Shah SJ, Anand IS, O’Meara E, Desai AS, Heitner JF, LIG, Fang J, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the
echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014;7:740–751. doi: 10.1161/CIRCHEARTFAILURE.114.001583
9. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection frac-
tion. Circulation. 2011;124:2491–2501. doi: 10.1161/CIRCULATIONAHA.110.110131
10. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Östergren J, McKelvie RS; Investigators of the CHARM Echocardiographic
Substudy-CHARMES. Diastolic dysfunction in heart failure with pre-
served systolic function: need for objective evidence: results from the
CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol. 2007;49:687–694. doi: 10.1016/j.jacc.2006.08.062
11. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–1360. doi: 10.1093/ehjci/jew082
12. van de Bovenkamp AA, Enait V, de Man FS, Oosterveer FTP, Bogaard HJ, Noordegraaf AV, van den Rossum AC, Handoko ML. Validation of the 2016 American Society of Echocardiography/European Association of
Cardiovascular Imaging Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction. J Am Heart Assoc. 2021;10:e021165. doi: 10.1161/JAHA.121.021165
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017
ACC/AHA/HFSA focused update of the 2013 ACC/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIRCU LATIO.117.005050
14. Opdahl A, Remme EW, Helle-Valle T, Lyseggen E, Vartdal T, Pettersen E, Edvardsen T, Smiseth OA. Determinants of left ventricular early-
diastolic lengthening velocity: independent contributions from left ven-
tricular relaxation, restoring forces, and lengthening load. Circulation. 2006;119:2578–2586. doi: 10.1161/CIRCULATIONAHA.106.671681
15. Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic ac-
ccuracy of tissue Doppler index E/e’ for evaluating left ventricular filling pressure and diastolic dysfunction/heart failure with preserved ejection
fraction: a systematic review and meta-analysis. J Am Heart Assoc. 2016;5:e002530. doi: 10.1161/JAHA.115.002530
16. Bhella PS, Piacini EL, Prasad A, Hastings JL, Adams-Huet B, Thomas JD, Grayburn PA, Levine BD. Echocardiographic indices do not reliably
track changes in left-sided filling pressure in healthy subjects or pa-
tients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging. 2011;4:482–489. doi: 10.1161/CIRCIMAGING.110.960575
17. Prasad A, Popovic ZB, Arbab-Zadeh A, Fu Q, Palmer D, Dijk E, Greenberg NL, Garcia MJ, Thomas JD, Levine BD. The effects of aging
and physical activity on Doppler measures of diastolic function. Am J Cardiol. 2007;99:1629–1636. doi: 10.1016/j.amjcard.2007.01.050
18. Shah AM, Claggett B, Kitzman D, Biering-Sørensen T, Jensen JS, Cheng S, Matsushita K, Komety S, Folsom AR, Mosley TH, et al. Contempo-
rary assessment of left ventricular diastolic function in older adults: the Atherosclerosis Risk in Communities Study. Circulation. 2017;135:426–439. doi: 10.1161/CIRCULATIONAHA.116.024825
19. Ha JW, Andersen OS, Smiseth OA. Diastolic stress test: invasive and
noninvasive testing. JACC Cardiovasc Imaging. 2020;13:272–282. doi: 10.1016/j.jcmg.2019.01.037
20. MacNamara JP, Ksoshti V, Cheng U, Dias KA, Hearon CM, Cornwell W III, Howden EJ, Levine BD, Sarma S. The role of systolic-diastolic
coupling in distinguishing impaired diastolic recoil in healthy aging
and heart failure with preserved ejection fraction. Echocardiography. 2021;38:261–270. doi: 10.1111/echo.14975